Financial Performance - Acurx Pharmaceuticals reported a net loss of 0.17 per diluted share for Q3 2024, compared to a net loss of 0.24 per diluted share for Q3 2023[12]. - General and administrative expenses for Q3 2024 were 1.8 million in Q3 2023, while total G&A expenses for the nine months ended September 30, 2024, increased to 5.4 million in the same period of 2023[11]. - Research and development expenses for Q3 2024 were 1.3 million in Q3 2023, while total R&D expenses for the nine months ended September 30, 2024, were 4.1 million in the same period of 2023[10]. Cash Position - The company ended Q3 2024 with cash totaling 7.5 million as of December 31, 2023, after raising approximately $1.6 million through its ATM financing program during the quarter[9]. - Acurx has 16,770,378 shares outstanding as of September 30, 2024[13]. Product Development - Acurx received a new patent for ibezapolstat, which will expire in June 2042, providing a competitive advantage in treating C. difficile infection[2]. - The company anticipates convening a meeting with the FDA regarding manufacturing processes in Q4 2024 to commence Phase 3 clinical trials for ibezapolstat[3]. - In the Phase 2b clinical trial, ibezapolstat demonstrated comparable clinical cure rates to vancomycin, with 5 out of 5 patients showing no recurrence after treatment[7]. - The company is developing ACX-375 DNA pol IIIC analogues for potential treatment against Anthrax, a Bioterrorism Category A pathogen[6]. Regulatory Initiatives - The company plans to continue international regulatory filing initiatives in Q4 2024[8].
Acurx Pharmaceuticals(ACXP) - 2024 Q3 - Quarterly Results